Peter Lawson
Stock Analyst at Barclays
(1.33)
# 3,553
Out of 4,984 analysts
99
Total ratings
38.37%
Success rate
-12.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $24.44 | +63.67% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $19.03 | +31.37% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $5.71 | -47.46% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $40.44 | -1.09% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.53 | +96.08% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $0.95 | +110.53% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.08 | +469.31% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $6.08 | +64.47% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.22 | +80.18% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $9.25 | -35.14% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $8.09 | +35.97% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $7.61 | +110.25% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $6.92 | +116.76% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $12.03 | +16.38% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.96 | +53.06% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.60 | +87.50% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.27 | +214.96% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $43.81 | +36.96% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $4.09 | +315.65% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $14.75 | +123.73% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $33.42 | +97.52% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $8.57 | +261.73% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $7.62 | +70.60% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.04 | +380.77% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $1.93 | +81.35% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $100.87 | +261.85% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $36.42 | +26.30% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $51.07 | +781.14% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.72 | +1,554.41% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $59.07 | -23.82% | 2 | Jan 23, 2018 |
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $24.44
Upside: +63.67%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $19.03
Upside: +31.37%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $5.71
Upside: -47.46%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $40.44
Upside: -1.09%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.53
Upside: +96.08%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $0.95
Upside: +110.53%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.08
Upside: +469.31%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $6.08
Upside: +64.47%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.22
Upside: +80.18%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $9.25
Upside: -35.14%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $8.09
Upside: +35.97%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.61
Upside: +110.25%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $6.92
Upside: +116.76%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $12.03
Upside: +16.38%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.96
Upside: +53.06%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.60
Upside: +87.50%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.27
Upside: +214.96%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $43.81
Upside: +36.96%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $4.09
Upside: +315.65%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $14.75
Upside: +123.73%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $33.42
Upside: +97.52%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $8.57
Upside: +261.73%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $7.62
Upside: +70.60%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.04
Upside: +380.77%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.93
Upside: +81.35%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $100.87
Upside: +261.85%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $36.42
Upside: +26.30%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $51.07
Upside: +781.14%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.72
Upside: +1,554.41%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $59.07
Upside: -23.82%